New mRNA shingles vaccine enters phase 2 trial – could it be a game changer?
NCT ID NCT07354659
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new mRNA vaccine called SYS6017 to prevent shingles, a painful rash caused by the chickenpox virus. About 800 healthy adults aged 40 and older will receive either the new vaccine, a placebo, or an existing shingles vaccine. Researchers will check how well the vaccine boosts the immune system and monitor for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HERPES ZOSTER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can mRNA technology outsmart shingles? a new vaccine trial aims to find out
- Shingles in cancer patients: a hidden cost burden?
- Shingles vaccine protection tested over 6 years in 24,740 adults
- New gel promises shingles pain relief in minutes
- Shingles shot may shield brain: 33,000 seniors test dementia link
- New shingles vaccine trial aims to protect millions over 40